Skip to main content
Premium Trial:

Request an Annual Quote

23andMe Gains FDA Clearance for Simvastatin Pharmacogenetic Report

NEW YORK – 23andMe said Thursday that it has received 510(k) clearance from the US Food and Drug Administration (FDA) for its pharmacogenetics report for SLCO1B1 that includes interpretive drug information for simvastatin. The clearance modifies labeling of a previously approved clearance for SLCO1B1 to remove a requirement for confirmatory testing before prescribing the drug for high cholesterol and triglycerides based on the 23andMe report.

To earn the right to remove the need for confirmatory testing, the consumer-focused genetics company provided the FDA with data showing that the 23andMe SLCO1B1 report was 99 percent in concordance with Sanger sequencing.

"This is an important win for consumers, as they will have access to critical information on how they may respond to a commonly prescribed medication, based on their genetics," Noura Abul-Husn, 23andMe's VP of genomic health, said in a statement. "With this clearance, we are continuing to champion access to actionable health information so that everyone can benefit from a personalized healthcare experience, and avoid negative side effects of medications where possible."

Simvastatin is sold as Zocor by Merck and as FloLipid by Salerno Pharma.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.